Incyte (INCY) insider trading
Insider activity, historical context and SEC filings · data through Nov 20, 2026
No open-market insider buying in the last 12 months. Selling alone is common (taxes, diversification, pre-planned 10b5-1 sales) and isn't treated as a signal here.
Label: Heavy selling · based on open-market trades (codes P and S), last 12 months. Not a rating or advice.- Next earnings expected around Jan 30, 2027 (estimate from past release dates). Insiders usually trade in the weeks after results; past reactions ↓
Sale Pablo J. Cagnoni, President sold 1,765 shares at $120.46 ($213K).
- Trade date
- Nov 16, 2026
- Disclosed to the SEC
- Nov 18, 2026
- Type
- Pre-planned sale, 10b5-1 (code S)
Read the original SEC filing ↗All INCY insider trades ↓
Insiders have two business days to report a trade to the SEC, so filings (and our alerts) always come after the trade, never in real time.
INCY insider transactions (Form 4)
Open-market purchases and sales. 137 grants, option exercises and tax withholdings are not shown.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Nov 18SEC | Pablo J. CagnoniPresident | Sell Plan | 1,765183,200 held (−1%) | $120.46 | $213K | -3.7% | — |
| Nov 18SEC | Pablo J. CagnoniPresident | Sell Plan | 877184,965 held (−0%) | $121.98 | $107K | -4.9% | — |
| Nov 18SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 57630,916 held (−2%) | $121.98 | $70K | -4.9% | — |
| Nov 17SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 3,70029,333 held (−11%) | $120.33 | $445K | -3.6% | — |
| Nov 17SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 2,44926,884 held (−8%) | $121.13 | $297K | -4.3% | — |
| Nov 17SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 2,20033,907 held (−6%) | $120.44 | $265K | -3.7% | — |
| Nov 17SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 1,47136,107 held (−4%) | $121.89 | $179K | -4.9% | — |
| Nov 17SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 87433,033 held (−3%) | $121.16 | $106K | -4.3% | — |
| Nov 10SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 73,96979,492 held (−48%) | $119.12 | $8.8M | -2.7% | — |
| Nov 10SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 60,270153,461 held (−28%) | $118.27 | $7.1M | -2.0% | — |
| Nov 10SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 48,57630,916 held (−61%) | $119.66 | $5.8M | -3.1% | — |
| Nov 10SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 35,042236,067 held (−13%) | $116.06 | $4.1M | -0.1% | — |
| Nov 10SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 22,336213,731 held (−9%) | $117.14 | $2.6M | -1.0% | — |
| Nov 5SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 61021,126 held (−3%) | $118.96 | $73K | -2.5% | — |
| Oct 19SEC | Pablo J. CagnoniPresident | Sell Plan | 2,642183,200 held (−1%) | $112.71 | $298K | +2.9% | — |
| Sep 17SEC | Pablo J. CagnoniPresident | Sell Plan | 13,985183,200 held (−7%) | $120.49 | $1.7M | -3.8% | — |
| Sep 17SEC | Pablo J. CagnoniPresident | Sell Plan | 9,233197,185 held (−4%) | $120.50 | $1.1M | -3.8% | — |
| Aug 20SEC | Pablo J. CagnoniPresident | Sell Plan | 10,801183,200 held (−6%) | $125.56 | $1.4M | -7.6% | — |
| Aug 14SEC | Pablo J. CagnoniPresident | Sell Plan | 10,803194,001 held (−5%) | $120.04 | $1.3M | -3.4% | — |
| Aug 7SEC | Pablo J. CagnoniPresident | Sell Plan | 10,640204,804 held (−5%) | $122.69 | $1.3M | -5.5% | — |
| Aug 7SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 2,20761,441 held (−3%) | $123.99 | $274K | -6.5% | — |
| Aug 4SEC | Pablo J. CagnoniPresident | Sell Plan | 15,888215,444 held (−7%) | $119.70 | $1.9M | -3.1% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 14,66188,679 held (−14%) | $119.46 | $1.8M | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 6,17174,989 held (−8%) | $119.43 | $737K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 6,05561,441 held (−9%) | $120.43 | $729K | -3.7% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 5,33283,347 held (−6%) | $119.42 | $637K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 4,69570,294 held (−6%) | $119.39 | $561K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 2,86467,430 held (−4%) | $119.40 | $342K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 2,29361,441 held (−4%) | $119.41 | $274K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 2,18781,160 held (−3%) | $119.47 | $261K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 1,64365,787 held (−2%) | $119.51 | $196K | -3.0% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 1,64264,145 held (−2%) | $119.38 | $196K | -2.9% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 32663,734 held (−1%) | $121.69 | $40K | -4.7% | — |
| Aug 4SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 8564,060 held (−0%) | $122.19 | $10K | -5.1% | — |
| Jul 20SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 1,87721,118 held (−8%) | $114.73 | $215K | +1.1% | — |
| Jul 20SEC | Mohamed Khairie IssaEvp, Head Of U.S. Commercial | Sell Plan | 1,09363,940 held (−2%) | $115.01 | $126K | +0.8% | — |
| Jul 16SEC | Steven H. SteinCmo & Head Of Late-Stage Dev. | Sell Plan | 28,23726,083 held (−52%) | $113.05 | $3.2M | +2.6% | — |
| Jun 8SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 2,63921,132 held (−11%) | $100.00 | $264K | +16.0% | — |
| May 28SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 2,05121,132 held (−9%) | $97.35 | $200K | +19.1% | — |
| May 21SEC | Paul J. ClancyDirector | Sell Plan | 15,00023,741 held (−39%) | $94.93 | $1.4M | +22.2% | — |
| Apr 21SEC | Pablo J. CagnoniPresident | Sell Plan | 18,667262,692 held (−7%) | $96.50 | $1.8M | +20.2% | — |
| Mar 19SEC | Pablo J. CagnoniPresident | Sell Plan | 18,667234,800 held (−7%) | $94.24 | $1.8M | +23.0% | — |
| Feb 23SEC | Pablo J. CagnoniPresident | Sell Plan | 18,668234,800 held (−7%) | $100.91 | $1.9M | +14.9% | — |
| Jan 8SEC | Mohamed Khairie IssaEvp, Head Of Us Oncology | Sell Plan | 10,85666,132 held (−14%) | $109.07 | $1.2M | +6.3% | — |
| Jan 7SEC | Steven H. SteinEvp & Chief Medical Officer | Sell Plan | 15,63434,203 held (−31%) | $101.70 | $1.6M | +14.0% | — |
| Dec 22SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 2,77422,973 held (−11%) | $100.00 | $277K | +16.0% | — |
| Dec 22SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 60022,973 held (−3%) | $98.25 | $59K | +18.0% | — |
| Dec 18SEC | Michael James MorrisseyEvp, Head Of Tech. Operations | Sell Plan | 53,17531,830 held (−63%) | $97.29 | $5.2M | +19.2% | — |
| Dec 18SEC | Michael James MorrisseyEvp, Head Of Tech. Operations | Sell Plan | 4,32327,507 held (−14%) | $97.26 | $420K | +19.2% | — |
| Dec 18SEC | Michael James MorrisseyEvp, Head Of Tech. Operations | Sell Plan | 83385,005 held (−1%) | $97.42 | $81K | +19.0% | — |
| Dec 12SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 5,55360,266 held (−8%) | $95.58 | $531K | +21.3% | — |
| Dec 12SEC | Patrick A. MayesEvp & Chief Scientific Officer | Sell Plan | 25560,011 held (−0%) | $94.94 | $24K | +22.1% | — |
| Dec 3SEC | Steven H. SteinEvp & Chief Medical Officer | Sell Plan | 20,10563,129 held (−24%) | $102.51 | $2.1M | +13.1% | — |
| Dec 3SEC | Steven H. SteinEvp & Chief Medical Officer | Sell Plan | 2,559100,327 held (−2%) | $102.96 | $263K | +12.6% | — |
| Nov 25SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 60023,573 held (−2%) | $103.00 | $62K | +12.6% | — |
| Nov 25SEC | Thomas TrayPrincipal Accounting Officer | Sell Plan | 16924,173 held (−1%) | $102.00 | $17K | +13.7% | — |
| Nov 19SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 27826,569 held (−1%) | $104.36 | $29K | +11.1% | — |
| Nov 12SEC | Herve HoppenotDirector | Sell Plan | 187,500329,646 held (−36%) | $105.46 | $19.8M | +10.0% | — |
| Nov 7SEC | Steven H. SteinEvp & Chief Medical Officer | Sell Plan | 5,233102,886 held (−5%) | $102.20 | $535K | +13.5% | — |
| Nov 6SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 59826,569 held (−2%) | $101.36 | $61K | +14.4% | — |
| Nov 5SEC | Lee HeesonEvp, Head Of Incyte Intl | Sell Plan | 3,07429,241 held (−10%) | $94.02 | $289K | +23.3% | — |
| Oct 17SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 27726,569 held (−1%) | $85.13 | $24K | +36.2% | — |
| Oct 6SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 3,50126,569 held (−12%) | $85.54 | $299K | +35.6% | — |
| Oct 6SEC | Sheila A. DentonGeneral Counsel | Sell Plan | 59933,200 held (−2%) | $87.65 | $53K | +32.3% | — |
Similar past setups: not applicable. INCY has had no open-market insider purchases in the last 12 months, so there's no buying setup to compare with history. When insiders buy, this section shows how 6,290 similar past buys did over 90 days. How we calculate this →
Play with INCY in the Research Lab
INCY has no open-market insider buys in the last 12 months. Try the tools with any setup.
Quick backtest: did buys like this beat the market?
Tap a setting to see how 6,290 past insider buys did.
Share price and insider trades
Incyte insider trading at a glance (Nov 20, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $67.8M of INCY stock on the open market; P/E 263.6 vs. a sector median of 25.0.
By InsiderPrint Research Desk · Updated · Sources: SEC EDGAR Form 4 filings, FINRA short-sale volume · How we calculate this
INCY insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $30.5M | 15 |
| Q3 2026 | — | 0 | $18.2M | 22 |
| Q2 2026 | — | 0 | $3.7M | 4 |
| Q1 2026 | — | 0 | $6.4M | 4 |
| Q4 2025 | — | 0 | $30.0M | 19 |
Valuation, profit and volume
Source: SEC filings, as of Nov 16, 2026. Volume and paper profit use daily closing prices.
Summary
Over the past 12 months, 0 Incyte insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $67.8M. Among insiders with enough purchase history to measure, Jean Jacques Bienaime (Director) has the highest Insider Score at 68. 64 of 64 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
INCY earnings: how the stock reacted
Each quarterly results release (SEC 8-K Item 2.02), the trend before it, insider trades in the 30 days before, and the 2-day market reaction. “E” marks releases on the chart above.
| Release | 15 days before | Insiders, 30 days before | Reaction (2 days) | Next 30 days |
|---|---|---|---|---|
| Oct 29, 2026 | +7.6% | Sold $298K | +3.0%S&P -2.1% | pending |
| Jul 28, 2026 | +1.9% | Sold $3.5M | +6.9%S&P -1.3% | -2.1% |
| Apr 28, 2026 | -0.4% | Sold $1.8M | +3.5%S&P -0.5% | -2.4% |
| Feb 10, 2026 | +6.9% | None | -9.3%S&P -0.3% | -6.4% |
| Oct 28, 2025 | +11.1% | Sold $376K | -3.1%S&P +0.3% | +15.8% |
| Jul 29, 2025 | +2.3% | None | +10.5%S&P -0.4% | +9.1% |
| Apr 29, 2025 | +4.7% | None | +5.3%S&P +0.7% | +3.8% |
| Feb 10, 2025 | +2.2% | None | -10.5%S&P +0.8% | +2.1% |
Most companies bar insiders from trading in the weeks before results, so pre-earnings purchases are rare and often made by directors or under pre-set plans. Past reactions don't predict future ones.
INCY short selling
Daily short-sale volume as a share of trading volume (FINRA), with the 20-day average.
This is short volume from off-exchange trades, not short interest. It includes market makers' routine hedging, so 40–50% is normal; what stands out is a ratio well above the stock's own average. Insiders buying while shorts pile in →
Insiders at Incyte
| Insider | Bought | Sold | Last filing | Past buys beat S&P | Score |
|---|---|---|---|---|---|
| Steven H. SteinCmo & Head Of Late-Stage Dev. | — | $36.4M | Nov 18, 2026 | — | — |
| Herve HoppenotDirector | — | $19.8M | Dec 10, 2025 | — | — |
| Pablo J. CagnoniPresident | — | $14.7M | Nov 18, 2026 | — | — |
| Patrick A. MayesEvp & Chief Scientific Officer | — | $6.6M | Aug 7, 2026 | — | — |
| Michael James MorrisseyEvp, Head Of Tech. Operations | — | $5.7M | Feb 4, 2026 | — | — |
| Lee HeesonEvp, Head Of Incyte Intl | — | $1.6M | Nov 17, 2026 | — | — |
| Paul J. ClancyDirector | — | $1.4M | Oct 2, 2026 | — | — |
| Mohamed Khairie IssaEvp, Head Of U.S. Commercial | — | $1.3M | Jul 20, 2026 | — | — |
| Thomas TrayPrincipal Accounting Officer | — | $952K | Nov 5, 2026 | — | — |
| Sheila A. DentonGeneral Counsel | — | $465K | Nov 19, 2025 | — | — |
| Edmund HarriganDirector | — | — | Oct 2, 2026 | — | — |
| Baker Bros. Advisors LPDirector | — | — | Oct 2, 2026 | — | — |
| David H. GardnerEvp, Chief Strategy Officer | — | — | Sep 24, 2026 | — | — |
| Ramitpal K. BasiEvp, Human Resources | — | — | Aug 27, 2026 | — | — |
| William MeuryCEO | — | — | Jul 20, 2026 | — | — |
| Richard A. HoffmanGeneral Counsel | — | — | Jul 20, 2026 | — | — |
| Otis W. BrawleyDirector | — | — | Jun 10, 2026 | 0 of 1 | — |
| Jean Jacques BienaimeDirector | — | — | Jun 10, 2026 | 2 of 2 | 68 |
| Jacqualyn A. FouseDirector | — | — | Jun 10, 2026 | — | — |
| Katherine A. HighDirector | — | — | Jun 10, 2026 | — | — |
| Suketu UpadhyayCFO | — | — | May 6, 2026 | — | — |
| Matteo TrottaEvp, Gm, Dermatology Us | — | — | Mar 26, 2026 | — | — |
Board links: companies that share insiders with INCY
Directors and executives who filed Form 4s for INCY and another company in the last 12 months.
- AAgilent Technologies Otis W. Brawley Director here · Director at A · latest filing Jun 10, 2026
- ASNDAscendis Pharma A/S Jean Jacques Bienaime Director here · Director at ASND · latest filing Aug 18, 2026
- IMNMImmunome Jean Jacques Bienaime Director here · Director at IMNM · latest filing Jun 10, 2026
- KROSKeros Therapeutics Jean Jacques Bienaime Director here · Director at KROS · latest filing Aug 19, 2026
- VRTXVertex Pharmaceuticals Suketu Upadhyay CFO here · Director at VRTX · latest filing May 6, 2026
- ZBHZimmer Biomet Suketu Upadhyay CFO here · CFO at ZBH · latest filing May 6, 2026
Insider activity at other Health Care companies
Same sector, ranked by insider buying in the last 90 days.
INCY stock: common questions
Are Incyte insiders buying INCY stock?
No. No Incyte insider reported an open-market purchase of INCY in the past 12 months.
Are Incyte insiders selling INCY stock?
8 insiders reported sales worth $67.8M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is INCY's P/E ratio?
INCY trades at about 263.6 times trailing earnings, compared with a median of 25.0 for the Health Care sector.
What is INCY's 52-week range?
Over the past year INCY has traded between $90.30 and $129.93. It last closed at $115.96 on Nov 19, 2026.